Lonny Levin

This inventor holds 7 USPTO granted patents. Top assignees: Cornell University, Kent University, Tri-Institutional Therapeutics Discovery Institute. Active years: 2003-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lonny Levin. Retrieved from https://idiyas.com/inventor/lonny-levin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 85.7

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 12(Granted Patents)

Company Filing History:

Tri-Institutional Therapeutics Discovery Institute

patents

where one patent can have more than one assignee

Years Active: 2003-2021

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10981899 - Inhibitors of soluble adenylyl cyclase (2021-04-20),

2. 9649295 - Chemical inhibitors of soluble adenylyl cyclase (sAC) (2017-05-16),

3. 9388250 - Method to treat psoriasis and other hyperproliferative skin disorders (2016-07-12),

4. 9095578 - Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens (2015-08-04),

5. 9017681 - Adenylyl cyclases as novel targets for antibactrial interventions (2015-04-28),

6. 8859213 - Method for diagnosing melanocytic proliferations (2014-10-14),

7. 6544768 - Mammalian soluble adenylyl cyclase (2003-04-08),

Title: Lonny Levin: Innovator in Soluble Adenylyl Cyclase Research

Introduction

Lonny Levin is a prominent inventor based in New York, NY (US), known for his significant contributions to the field of biochemistry and pharmacology. He holds a total of 7 patents, focusing on innovative methods and compounds that target soluble adenylyl cyclase, a crucial enzyme in various physiological processes.

Latest Patents

Levin's latest patents include groundbreaking work on inhibitors of soluble adenylyl cyclase. One of his notable inventions involves 6-amino substituted 2,6-diamino-4-chloropyrimidine compounds, which serve as specific inhibitors of soluble adenylyl cyclase. These compounds can be formulated with pharmaceutical carriers and are intended for reducing cyclic AMP levels, with potential applications in treating conditions such as ocular hypotony. Another significant patent relates to a method of treating disorders mediated by soluble adenylyl cyclase. This method involves administering an effective amount of a compound that modulates soluble adenylyl cyclase to treat various disorders, including learning or memory disorders, malaria, fungal infections, spinal cord injuries, Alzheimer's disease, amyotrophic lateral sclerosis, and peripheral neuropathy.

Career Highlights

Throughout his career, Lonny Levin has been associated with esteemed institutions such as the Cornell Research Foundation Inc. and Cornell University. His work has significantly advanced the understanding of soluble adenylyl cyclase and its implications in various medical conditions.

Collaborations

Levin has collaborated with notable colleagues in his field, including Jochen Buck and Leo Brizuela. These partnerships have contributed to the development of innovative solutions in the realm of biochemistry.

Conclusion

Lonny Levin's contributions to the field of soluble adenylyl cyclase research exemplify his dedication to innovation and invention. His patents and collaborations continue to influence the development of therapeutic strategies for various medical conditions.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]